Document:

EX-10.1

 Exhibit 10.1 

FORM OF 
 CONSENT AND
AMENDMENT TO SUBSCRIPTION AGREEMENT 
 This Consent and Amendment (this “Amendment”) to the Subscription Agreement,
dated as of May 25, 2021 (the “Subscription Agreement”), by and between Foresight Acquisition Corp. (“Foresight”), and the undersigned person or entity (the “Subscriber”) is effective as of
November 19, 2021. Foresight and the Subscriber are collectively referred to herein as the “Parties”. All capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the
Subscription Agreement. 
 WHEREAS, the Parties desire to amend the Subscription Agreement in accordance with Section 11(f)
thereof to provide that the Subscription Agreement may be terminated at the election of the Subscriber if the Transaction Closing shall not have occurred by December 8, 2021; 

WHEREAS, the Transaction Agreement will be amended to extend the Outside Date (as defined in the Transaction Agreement) from
November 25, 2021, to December 8, 2021 (the “Transaction Agreement Amendment”); and 
 WHEREAS, the
Subscriber desires to consent to the Transaction Agreement Amendment. 
 NOW THEREFORE, in consideration of the mutual promises and
agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound, the Parties agree as follows: 

Section 1. Amendment to Section 8 of the Subscription Agreement. Clause (d) of Section 8 of the
Subscription Agreement is hereby deleted in its entirety and replaced with the following: 
 “(d) at the election of the
Subscriber, if the Transaction Closing shall not have occurred by December 8, 2021;” 
 Section 2. Consent of
Subscriber. The Subscriber hereby consents to the Transaction Agreement Amendment. 
 Section 3. No Other Amendments;
Other Provisions. Except as expressly amended by this Amendment, the Subscription Agreement will remain in full force and effect without any amendment or other modification thereto, and all of the provisions of the Subscription Agreement are
equally applicable to this Amendment. On and after the date hereof, each reference in the Subscription Agreement to “this Subscription Agreement,” “hereunder,” “hereof,” “herein” or words of like import
referring to the Subscription Agreement, and each reference in any other document (including, without limitation, the Transaction Agreement of like import referring to the Subscription Agreement, means and references the Subscription Agreement as
amended hereby. 
 (Signature Page Follows) 

 IN WITNESS WHEREOF, the undersigned has executed or caused this Consent and Amendment
to be executed by its duly authorized representative as of the date set forth below. 
  

			
	Name of Subscriber:
		
	By:	 	
                     
    

	Name:	 	
                     

	Title:	 	
                     

 Date: November 19, 2021 

 IN WITNESS WHEREOF, Foresight Acquisition Corp. has executed this Consent
and Amendment as of the date set forth below. 
  

			
	FORESIGHT ACQUISITION CORP.
		
	By:	 	
                     
    

	Name:	 	
                     
    

	Title:	 	
                     
    

 Date: November 19, 2021Adamis Pharmaceuticals, Corporation 10-Q

     

Exhibit 10.1

 

[***]  Certain information
in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and is
the type that the Registrant treats as private or confidential.

SETTLEMENT AGREEMENT

 

This Settlement
Agreement (“Agreement”) is entered into among Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron
Sterile Compounding Center, LLC (“Nephron” or “Plaintiff’), and U.S. Compounding, Inc. (“U.S.
Compounding”), Adamis Pharmaceuticals Corporation (“Adamis”), Jennifer Shelly Hulsey (“Hulsey”),
and Jessica Ingrid Lane (“Lane”) (together hereinafter “Defendants”). Nephron and Defendants are
collectively hereinafter referred to as the “Parties”.

RECITALS

WHEREAS,
Nephron Pharmaceuticals Corporation is a corporation organized and existing under and by virtue of the laws of the State of Florida
with its principal place of business located at 4121 SW 34th Street, Orlando, Florida, 32811;

WHEREAS,
Nephron S.C., Inc. is a corporation organized and existing under and by virtue of the laws of the State of South Carolina with its
principal place of business located at 4500 12th Street Extension, West Columbia, South Carolina, 29172;

WHEREAS, Nephron Sterile Compounding Center,
LLC a corporation with its principal place of business located at 4500 12th Street Extension, West Columbia, South Carolina,
29172;

WHEREAS,
U.S. Compounding, Inc. is a corporation organized and existing under and by virtue of the laws of the State of Arkansas with its principal
place of business located at 1270 Don’s Lane, Conway, Arkansas, 72032;

WHEREAS,
Adamis Pharmaceuticals Corporation is a California corporation that is the parent corporation of U.S. Compounding with its principal place
of business located at 11682 El Camino Real, Suite 300, San Diego, California, 92130;

WHEREAS, Shelly Hulsey is a natural person domiciled
in the State of Kansas;

WHEREAS, Jessica Lane is a natural person domiciled
in the State of New Jersey;

WHEREAS,
on September 21, 2018, Nephron commenced litigation in the United States District Court for the Middle District of Florida (the “Florida
Court”), styled Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron Sterile Compounding Center, LLC v.
Jennifer Shelly Hulsey and U.S. Compounding, Inc. d/b/a U.S. Compounding Pharmacy, originally assigned case number 6:18-cv-1573-ORL-31-KRS
and ultimately assigned case number 6:18-cv-01573-GAP-LRH (the “Florida Lawsuit”), alleging, without limitation, that
Hulsey and U.S. Compounding collectively misappropriated certain trade secrets from Nephron;

WHEREAS,
on March 1 , 2019, Nephron filed a second amended complaint in the Florida Lawsuit, adding Adamis as a defendant, and alleging
various claims against Hulsey, U.S. Compounding, and Adamis including, without limitation, that they collectively misappropriated certain
trade secrets from Nephron;

Page 1 of 12

    	 

    	 

    

WHEREAS,
on July 1 , 2019, Nephron filed a third amended complaint in the Florida Lawsuit, alleging various claims against Hulsey, U.S.
Compounding, and Adamis including, without limitation, that Hulsey, U.S. Compounding, and Adamis collectively misappropriated certain
trade secrets from Nephron;

WHEREAS,
on October 10, 2019, Hulsey filed for Chapter 13 bankruptcy in her individual capacity in the United States Bankruptcy
Court for the District of Kansas (the “Bankruptcy Court”), which matter is styled In re: Hulsey, case number
19-22173-13 (the “Bankruptcy”);

WHEREAS,
on December 19, 2019, Nephron filed its original proof of claim in the Bankruptcy and later filed an amended proof of claim in
the Bankruptcy on February 26, 2021 (the “Proof of Claim”);

WHEREAS, on June 9, 2020, Nephron filed its Objection
to Confirmation of Second Amended Chapter 13 Plan in the Bankruptcy (the “Objection to Plan”);

WHEREAS,
on January 6, 2020, Nephron filed an adversary complaint in the Bankruptcy, styled Nephron Pharmaceuticals Corporation,
Nephron S.C., Inc., and Nephron Sterile Compounding Center, LLC v. Jennifer Shelly Hulsey, assigned case number 20-06002 (the
“Adversary Proceeding”) in which Nephron asserted causes of action for exception to discharge under 11 U.S.C. §
523  against Hulsey arising from Nephron’s allegations that Hulsey misappropriated trade secrets from Nephron;

WHEREAS, on
February 26, 2020, Nephron filed a complaint in the United States District Court for the District of New Jersey (the “New Jersey
Court”), styled Nephron Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron Sterile Compounding Center, LLC v.
Jessica Ingrid Lane, U.S. Compounding, Inc. d/b/a U.S. Compounding Pharmacy, and Adamis Pharmaceuticals Corporation, case number
3:20-cv-02089-FLW-LHG (the “New Jersey Lawsuit”), alleging, without limitation, that Lane, U.S. Compounding, and Adamis
collectively misappropriated certain trade secrets from Nephron;

WHEREAS,
on December 16, 2020, the New Jersey Court issued an order transferring Nephron’s claims against Lane individually to the United
States District Court for the District of South Carolina, Columbia Division (the “South Carolina Court”), styled Nephron
Pharmaceuticals Corporation, Nephron S.C., Inc., and Nephron Sterile Compounding Center, LLC Jessica Ingrid Lane, case number 3:20-cv-04356-MGL-PJG (the “South Carolina Lawsuit”);

WHEREAS,
Nephron, Adamis, U.S. Compounding, and Hulsey filed a Notice of Resolution with the Florida Court related to the Florida Lawsuit on April
9, 2021 indicating that they had reached settlement of the Florida Lawsuit;

WHEREAS,
the Parties have reached a mutually agreeable settlement related to the Florida Lawsuit, the New Jersey Lawsuit, the South Carolina Lawsuit,
the Proof of Claim, and the Adversary Proceeding, and desire to memorialize the terms of their settlement through this Agreement;

 

Page 2 of 12

    	 

    	 

    

WHEREAS,
by executing this Agreement, the Parties desire to fully and finally settle all claims and disputes between and among them which arise
from or relate in any manner to the allegations made by Nephron in the Florida Lawsuit, the New Jersey Lawsuit, the South Carolina Lawsuit,
the Bankruptcy, and the Adversary Proceeding;

NOW,
THEREFORE, in consideration for the mutual promises, covenants, agreements, and undertakings contained herein, and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

AGREEMENT

 

1.                   
Settlement Payment. Adamis and/or U.S. Compounding will pay Nephron the total sum
of Seven Million Nine Hundred Thousand Dollars and OO/ lOOths Cents ($7,900,000.00 USD) (the “Settlement Payment”) on
or before five o’clock p.m. EDT on the seventh calendar day following the Effective Date of this Agreement (defined below). The
Settlement Payment shall be paid in the form of one lump sum payment wired to Nephron in accordance with the instructions to be provided
by counsel for Nephron to counsel for Adamis and U.S. Compounding. Counsel for Adamis and U.S. Compounding shall notify counsel for Nephron
the date the Settlement Payment is wired to Nephron and shall provide Nephron’s counsel documentation sufficient to confirm the
same.The Parties agree that the Settlement Payment shall be treated, for tax purposes, as compensatory damages paid to Nephron to
resolve the Florida Lawsuit, the New Jersey Lawsuit, and the South Carolina Lawsuit.

 

2.                   
Consent Permanent Injunction; Required Declarations: Final Resolution of the Florida, South
Carolina, and New Jersey Lawsuits, and the Adversary Proceeding; and Withdrawal of Proof of Claim in Bankruptcy. The Parties
agree to the entry of the Stipulation for Entry of Consent Permanent Injunction Order and Stipulated Final Judgement (the “Injunction”)
in the form attached hereto as Exhibit A. the terms being expressly incorporated herein by reference, in the Florida Lawsuit,
and to the entry of the same in a substantially similar form in the New Jersey Lawsuit, and the South Carolina Lawsuit, to account for
the appropriate parties and captions. If the Florida Court, New Jersey Court, or the South Carolina Court requests or requires any additional
filing(s) or document(s) to support the entry of the Injunction as a final judgment resolving the Florida Lawsuit, the New Jersey Lawsuit,
and/or the South Carolina Lawsuit and dismissing Nephron’s claims with prejudice, the Parties agree to cooperate in the preparation
and filing of the same by and through their counsel in a manner consistent with the terms of this Agreement.

Further, Lane
agrees to submit a declaration to counsel for Nephron certifying that she has permanently and irrevocably destroyed any and all information,
data, and documents, whether electronic or hard copy, that concern or relate in any manner to Nephron (hereafter “Nephron Information”),
and that are in her custody, control, or possession, or to which she otherwise has access (whether on an electronic device or in a personal
account such as, without limitation, an iCloud or an email account), and further swearing that she is no longer has custody, control,
or possession of, or any access to, Nephron Information including, without limitation, copies of Nephron Information (the “Lane
Declaration”). The Lane Declaration shall include, without limitation, a sworn statement verifying that Lane has permanently
deleted and destroyed any and all Nephron Information including, without limitation, copies thereof, which are or were at one time

 

Page 3 of 12

    	 

    	 

    

stored
in any of Lane’s personal iCloud account(s). In addition, Hulsey agrees to submit a declaration to Nephron certifying that she has
permanently and irrevocably destroyed any and all Nephron Information, whether electronic or hard copy, that is in her custody, control,
or possession, or to which she otherwise has access (whether on an electronic device or in a personal account such as, without limitation,
an iCloud or an email account), and further swearing that she is no longer has custody, control, or possession of, or any access to, Nephron
Information including, without limitation, copies of Nephron Information (the “Hulsey Declaration”). Hulsey agrees
to work with Nephron to reach a mutual agreement regarding the deletion of Nephron Information from her devices and the third party devices
that contain Nephron Information and that are in the possession of the forensic neutral engaged by the Parties in the Florida Litigation
pursuant to the Stipulated Forensic Protocol therein.

Nephron
agrees that, following: (i) its receipt of the Settlement Payment described at Paragraph 1 above; (ii) its receipt of the executed Lane
Declaration and the Hulsey Declaration containing the certifications set forth above; and (iii) the entry of the Permanent Injunction
by the Florida Court in the Florida Lawsuit, the New Jersey Court in the New Jersey Lawsuit, and the South Carolina Court in the South
Carolina Lawsuit, it will: (i) if required by the Florida Court, the New Jersey Court, the South Carolina Court, file a stipulation of
dismissal with prejudice in the Florida Lawsuit, the New Jersey Lawsuit, the South Carolina lawsuit, and the Adversary Proceeding, dismissing
all of its claims asserted in each; and (ii) withdraw both its Proof of Claim and its Objection to Plan filed in the Bankruptcy. Hulsey
specifically agrees to fully cooperate and take whatever steps are necessary in order to have the Bankruptcy Court lift the automatic
stay for the purpose of permitting the Parties to have the Injunction entered on the docket in the Florida Court and to effectuate the
terms of this Agreement.

 

3.                   
Effective Date. This Agreement shall be effective once executed by all Parties (the
“Effective Date”) and shall be of no force and effect until such time.

4.                  
Mutual Releases and Covenants Not to Sue.  Upon the Effective Date, Nephron, on the
one hand, and Defendants, on the other hand, shall mutually release and forever discharge each other from any and all claims, rights,
actions, causes of action, suits, damages, losses, attorneys’ fees, costs, expenses, payments, debts, grievances, and liabilities
that were raised or that could have been raised in the Florida Lawsuit, the New Jersey Lawsuit, the South Carolina Lawsuit, and/or the
Adversary Proceeding (hereinafter collectively the “Lawsuits”) in any form, or that arise from or relate to the claims
and liabilities asserted in the Lawsuits, including but not limited to related claims, cross-claims, or collateral claims, whether known
or unknown, asserted or not yet asserted, vested or contingent. Hulsey, Lane, and Nephron each affirm, acknowledge, and agree that this
release language is intended to and does include, without limitation, a mutual release of any and all claims, rights, actions, causes
of action, suits, damages, losses, attorneys’ fees, costs, expenses, payments, debts, grievances, and liabilities concerning or
related in any manner to their former employment with Nephron including, without limitation, their separation therefrom. This release
language is for any relief, no matter how described, including but not limited to back pay, front pay, compensatory damages, liquidated
damages, punitive damages, damages for pain and suffering, emotional distress, or mental anguish, statutory damages, court costs and
litigation expenses, and attorneys’ fees and costs.

 

Page 4 of 12

    	 

    	 

    

Also
upon the Effective Date, Nephron, on the one hand, and Defendants, on the other hand, hereby absolutely, unconditionally and irrevocably,
covenant and agree that they will not sue (at law, in equity, in any regulatory proceeding or otherwise) one another on the basis of any
claim released pursuant to the above release. If any Party violates the foregoing covenant, the violating Party agrees to pay, in addition
to such other damages that any other Party may sustain as a result of such violation, all reasonable attorneys’ fees and costs incurred
by such other Party as a result of such violation.

 

Notwithstanding
the above, the releases and covenants under this paragraph do not constitute releases of any Party’s ongoing obligations under this
Agreement, or of any claims or causes of action arising under or resulting from a default or breach of this Agreement.

5.                 
Representations and Warranties of the Parties.

(a)           Each undersigned corporate Party represents
and warrants that it has the full power and authority to enter into this Agreement, and that the persons executing this Agreement on
each of their respective behalves are duly authorized to do so and have the necessary capacity to do so.

(b)
          Each undersigned individual Party represents and warrants
that she has the full power and authority to enter into this Agreement, and
that she the necessary capacity to do so.

(c)           The Parties represent and warrant that they have, prior to entering into this Agreement,
been advised in writing to consult with counsel and that they have had the provisions of this Agreement explained, reviewed, and approved
by their attorneys. The Parties also acknowledge that they have been given a reasonable period of time to study, analyze, and evaluate
this Agreement before signing it and has been given the opportunity to negotiate this Agreement at arm’s length. The Parties therefore
waive any common law or statutory rule of construction that ambiguities be construed against the drafter of this Agreement.

(d)               
The Parties acknowledge that they are executing this Agreement freely, knowingly, and voluntarily,
that they are fully aware of the contents and effects thereof, and that the execution of this Agreement is not the result of any fraud,
duress, mistake, coercion, or undue influence.

6.                   
Binding Effect. This Agreement shall be binding upon each of the Parties and their
respective successors-in-interest.

7.                   
Court Jurisdiction.  The Parties consent to the exclusive jurisdiction of the U.S.
District Court for the Middle District of Florida (the “Florida Court,” as specified above) for purposes of the enforcement
of this Agreement and the Injunction entered in the Florida Lawsuit (the “Florida Injunction”). Any claims or causes
of action, whether legal or equitable, arising out of or based upon this Agreement or the Florida Injunction, including, but not limited
to, the interpretation and/or enforcement of this Agreement or the Florida Injunction, shall be commenced in the Florida Court. The Parties
hereby expressly consent to the Florida Court’s jurisdiction over any claims or actions arising out of the enforcement of this
Agreement and/or the Florida Injunction and irrevocably waive any and all jurisdictional or other defenses to the enforceability of the
Agreement and/or the Florida Injunction. The Parties consent to the exclusive jurisdiction for the U.S. District Court of New Jersey
(the “New Jersey Court,” as specified above) for purposes of the

 

Page 5 of 12

    	 

    	 

    

enforcement
of the Injunction as entered in the New Jersey Lawsuit (the “New Jersey Injunction”), and agree that any claims or
causes of action, whether legal or equitable, arising out of or based upon the New Jersey Injunction including, but not limited to, the
interpretation and/or enforcement of the New Jersey Injunction, shall be commenced in the New Jersey Court. The Parties hereby expressly
consent to the New Jersey Court’s jurisdiction over any claims or actions arising out of the enforcement of the New Jersey Injunction
and irrevocably waive any and all jurisdictional or other defenses to the enforceability of the New Jersey Injunction. The Parties consent
to the exclusive jurisdiction for the U.S. District Court of South Carolina, Columbia Division (the “South Carolina Court,”
as specified above) for purposes of the enforcement of the Injunction as entered in the South Carolina Lawsuit (the “South Carolina
Injunction”), and agree that any claims or causes of action, whether legal or equitable, arising out of or based upon the South
Carolina Injunction including, but not limited to, the interpretation and/or enforcement of the South Carolina Injunction, shall be commenced
in the South Carolina Court. The Parties hereby expressly consent to the South Carolina Court’s jurisdiction over any claims or
actions arising out of the enforcement of the South Carolina Injunction and irrevocably waive any and all jurisdictional or other defenses
to the enforceability of the South Carolina Injunction.

8.                   
Governing Law. This Agreement is made pursuant to, and shall be governed by, the laws
of the State of Florida and, where applicable, federal law.

9.                   
Integration and Amendments. Excepting only Hulsey and Lane’s obligations surviving
their separation from employment with Nephron as expressly set forth in their respective Employee Confidentiality and Non-Disclosure
Agreements (the “NDAs”) that Hulsey executed on June 17, 2015, and that Lane executed on or about July 26, 2017, which
obligations remain in full force and effect and are incorporated fully herein by reference, this Agreement constitutes the complete,
and entire agreement and understanding of and among the Parties in relation to matters described herein and supersedes all prior oral
or written agreements and/or negotiations with respect to the matters addressed herein. Any such obligations under the NDAs are in addition
to, and not in lieu of, the obligations under the Injunction. Any amendment or modification to this Agreement must be in writing, signed
by duly authorized representatives of the Parties hereto, and specifically state the intent of the Parties to amend and/or modify this
Agreement. In the event of a conflict between the NDAs and this Agreement and/or the Injunction, this Agreement and/or the Injunction,
as applicable, shall control.

10.                 
Severability. If any particular paragraphs, subparagraphs, phrases, words, or other
portions of this Agreement are determined by any court of competent jurisdiction to be invalid or unenforceable as written, they shall
be modified as necessary to comport with the reasonable intent and expectations of the Parties, and such modification shall not affect
the remaining provisions of this Agreement, or if they cannot be modified to be made valid or enforceable, then they shall be severed
from this Agreement, and all remaining terms and provisions shall remain enforceable, provided that the primary purposes of this Agreement
are not frustrated.

11.                 
Counterparts. This Agreement may be executed by the Parties hereto in counterparts,
each of which, once executed and delivered in accordance with the terms of this Agreement, will be deemed an original, with all such
counterparts taken together constituting one and the same instalment. Delivery by facsimile, encrypted e-mail, or e-mail file attachment
of any

 

Page 6 of 12

    	 

    	 

    

 

such executed counterpart to this Agreement will be
deemed the equivalent of the delivery of the original executed agreement or instrument.

12.                   
Waiver. Any Party’s failure to enforce any provision(s) of this Agreement shall
not in any way be construed as a waiver of that provision(s) or prevent that party thereafter from enforcing each and every provision
of this Agreement.

13.                   
Material Breach. The Parties acknowledge and agree that even if any Party violates
any term of this Agreement, all provisions of this Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, the undersigned Parties
have caused this Agreement to be duly executed as of the Effective Date set forth in this Agreement:

 

 

[SIGNATURE
PAGES FOLLOW FOR EACH PARTY INDIVIDUALLY]

 

Page 7  of 12

    	 

    	 

    
Nephron Pharmaceuticals Corporation,  Nephron S.C., Inc., and Nephron Sterile Compounding Center, LLC

Signed:

/s/ Lou Kennedy

By: Lou Kennedy

Chief Executive Officer

 

 

Page 6  of 12

    	 

    	 

    
 

U.S. Compounding, Inc.

 

Signed:

 

/s/ Robert O. Hopkins

By: Robert O. Hopkins

Its: CFO

 

 

[***]

 

 

 

Page 9  of 12

    	 

    	 

    

 

 

/s/ Jennifer Shelley Hulsey

 

/s/ Jessica Ingrid Lane

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]